SWOG clinical trial number
CTSU/E2204

An Intergroup Randomized Phase II Study of Bevacizumab (NSC 704865) or Cetuximab (NSC 714692) in Combination with Gemcitabine and in Combination with Chemoradiation (Capecitabine and Radiation) in Patients with Completely-Resected Pancreatic Carcinoma

Closed
Phase
Abbreviated Title
PANCREAS
Activated
10/15/2006
Closed
01/09/2008
Participants
CTSU

Research committees

Gastrointestinal Cancer

Treatment

Gemcitabine hydrochloride Radiation Therapy Bevacizumab Capecitabine Cetuximab

Eligibility Criteria Expand/Collapse

The Southwest Oncology Group participated in this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.

Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (http://www.ctsu.org/) for more information.

Publication Information Expand/Collapse

2010

ECOG 2204: An intergroup phase II study of cetuxamab (Ce) or bevacizumab (B) in combination with gemcitabine (G) and in combination with capecitabine (Ca) and radiation (XRT) as adjuvant therapy (Adj Tx) for patients (pts) with completely resected pancreatic adenocarcinoma (PC)

J Berlin;PJ Catalano;Y Feng;AM Lowy;AW Blackstock;PA Philip;RR McWilliams;J Abbruzzese;AB Benson Journal of Clinical Oncology 28:7s (suppl; abstr 4024) poster